OGEN today
$0.34+$0.00 (+1.14%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minLeaning Bearish
5 minConsolidating
Daily trend turns up above $0.53
Key levels
Resistance$0.49
Resistance$0.46
Latest news & SEC filings
ProductOragenics doses 9 in Phase IIa study, receives NYSE American deficiency notice
All OGEN news →About Oragenics
Oragenics is an early-stage drug developer working on medicines given through the nose. Its main program uses a man-made neurosteroid, ONP-002, delivered by a breath-powered nasal spray device, aimed at treating concussion. The company runs laboratory and human studies in the U.S. and Australia and has no products approved for sale.
Based on the company's 10-K filed Mar 16, 2026.
NYSE · Healthcare
ORAGENICS INC (OGEN)
What Is the Price Target for OGEN?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is OGEN a Buy or Sell Right Now?
Thesis
- •Revenue growing -71.4% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for OGEN.
Start Free Trial →Is OGEN Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
PEG
Fair Value
$-0.46
12
Moat Score
NONE
3/9
Piotroski Score
-34.3
Altman Z-Score
What Is Smart Money Doing with OGEN?
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →OGEN Growth Story
Revenue YoY
-71.4%
3yr Revenue CAGR
N/A%
EPS Growth YoY
90.48%
FCF Growth YoY
N/A%
Revenue Trend
DECLINING
Dark Pool Trades for OGEN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for OGEN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:55:16 | $0.34 | 2,406 | $$824 | SELL |
| 17:15:15 | $0.36 | 2,000 | $$721 | MIDPOINT |
| 19:37:27 | $0.35 | 1,000 | $$349 | SELL |
| 14:48:18 | $0.35 | 1,129 | $$395 | BUY |
| 19:58:00 | $0.35 | 1,808 | $$624 | SELL |
5 dark pool trades shown · $$3K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ORAGENICS INC (OGEN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →OGEN — frequently asked questions
What is OGEN stock price today?
ORAGENICS INC (OGEN) is at $0.34, up 1.14% (+$0.00) at the Nov 12, 2026 close.
Why is OGEN stock moving today?
Latest OGEN news — Aug 28, 2026: Oragenics doses 9 in Phase IIa study, receives NYSE American deficiency notice
Did OGEN beat earnings?
OGEN last reported on Aug 13, 2026: EPS -$0.57 vs -$90.00 expected — a beat of 99.4%.
What is OGEN's P/E ratio?
OGEN trades at a P/E of 0.3 vs a Healthcare average of 17.7.
Does OGEN pay a dividend?
OGEN does not currently pay a dividend.
What are OGEN support and resistance levels?
Resistance: $0.46, $0.49, $0.52.
What are insiders doing with OGEN?
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
What is the latest news on OGEN?
Aug 28, 2026: Oragenics doses 9 in Phase IIa study, receives NYSE American deficiency notice